A phase 3 trial of intralesional cemiplimab in patients with early-stage cutaneous SCC, newly underway at GW and multiple other sites, will look at how well the immune checkpoint inhibitor ... from ...

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20 ...

Sun Pharma will also launch skin cancer drug Unloxcyt in FY26. The drug was incorporated into Sun’s portfolio after the acquisition of Checkpoint Therapeutics in March this year for an upfront ...

Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing.

Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday ...

CHENNAI: India’s largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 mil ...

Sun Pharmaceutical Industries on Friday announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. (Checkpoint), an immunotherapy and targeted oncology company.As part ...

The merger arrives as Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)’s market cap stands at $370.71 million. With the deal valued at $416 million, the premium paid by Sun Pharma signals confidence ...

Checkpoint Therapeutics, Inc. announced the completion of a merger on May 30, 2025, with Snoopy Merger Sub, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries, Inc.As part of the ...

Sun Pharma appoints Kirti Ganorkar as new MD: Mo: Stock Alert: NTPC, Arkade Developers, ITC, Spicejet, Sun Pharma, Syngene Intl: 04.06. Sun Pharma Advanced Research Company Ltd leads losers in 'A ...

Upon completion of the transaction, Sun Pharma acquired all outstanding shares of Checkpoint for $4.10 per share in cash and a non-transferable CVR entitling the stockholder to receive up to an ...